Navigation Links
AssureRx Adds VP of Sales and Marketing
Date:4/28/2008

Personalized medicine company prepares for commercial launch of first

product

CINCINNATI, April 28 /PRNewswire/ -- AssureRx, a personalized medicine company, announced that Al Lucas has joined the Company as vice president of sales and marketing. He will be responsible for developing the marketing plan and initial launch strategy, building the sales force, and leading the commercial introduction of the Company's first product. Lucas is an experienced pharmaceutical sales and marketing leader with more than 20 years of experience at companies such as Novartis, Pharmacia, and The Upjohn Company. In his various roles with those companies, he has participated in more than 15 successful product launches, including the highly successful Zyvox (linezolid). Additionally, he played roles in the planning, hiring and training of multiple sales forces.

"I was very excited about the opportunity to join AssureRx in this early stage," said Lucas. "The personalized medicine movement will change the way medicine is practiced, and AssureRx has positioned itself to become the market leader within the largest potential segment, the neuropsychiatric field. The Company has solid relationships with the thought leaders in psychopharmacogenetic research, which supports the development of our products. We will leverage this cutting-edge technology to bring tools to the marketplace which will help physicians provide individualized and highly-specific care to each patient," Lucas continued. "These are the hallmarks of personalized medicine."

Mark Byrne, AssureRx CEO added, "We are extremely pleased that Al has joined AssureRx. He brings a demonstrated track record of successful new product introductions and is experienced in the neuro-pscyh market segment. The addition of Al will accelerate our commercial introduction."

About AssureRx

AssureRx, LLC, is a personalized medicine company dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from a range of medical conditions. The company was founded in June 2006 to license and commercialize the industry-leading personalized medicine technology of Cincinnati Children's Hospital and the Mayo Clinic. The proprietary technology is based on pharmacogenetics -- the study of the genetic factors that influence an individual's response to drug treatments -- as well as evidence-based medicine and clinical pharmacology. The result is a trusted guide that helps doctors select the right drug at the right dose right now.


'/>"/>
SOURCE AssureRx, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test
2. Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
5. VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales
6. Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business
7. Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
8. Dilon Technologies Closes First Quarter With Record Sales
9. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... Information Management Services ( IMS ) is pleased to announce a major upgrade ... and is so significant it was endowed with a new name, BSI Engage. ... a streamlined layout and a more intuitive format for navigating the system. ...
(Date:2/8/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, ... mobile-friendly. Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create ...
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/4/2016)... 4, 2016 - New FDA action date of ... New FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast ... decade indicated for the treatment of signs and symptoms of dry ... the potential to be the only product approved in the U.S. in the past decade ...
Breaking Biology Technology:
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
Breaking Biology News(10 mins):